User login
Key clinical point: In patients with intermediate-/high-risk prostate cancer undergoing radical prostatectomy and lymph node dissection, Gallium 68 prostate-specific membrane antigen (68Ga-PSMA)-11 positron emission tomographic (PET) imaging shows sensitivity and specificity of 0.40 and 0.95, respectively.
Major finding: Compared with histopathology, 68Ga-PSMA-11 PET imaging showed a sensitivity, specificity, positive predictive value, and negative predictive value for pelvic nodal metastases of 0.40, 0.95, 0.75, and 0.81, respectively.
Study details: A single-arm, open-label, phase 3 imaging trial (NCT03368547, NCT02611882, and NCT02919111) of 764 patients with intermediate- to high-risk prostate cancer considered for prostatectomy who underwent 68Ga-PSMA-11 PET scan.
Disclosures: This work is supported by grants from the National Cancer Institute, Prostate Cancer Foundation, Society of Nuclear Medicine and Molecular Imaging, Philippe Foundation Inc, ARC Foundation, German Research Foundation, Doctor Robert Pfleger Foundation, and Wiedenfeld Foundation. The authors received grants, personal fees, cooperation projects, and speaker/advisory/consulting fees; held a patent; and/or reported being founder/shareholder outside this work.
Source: Hope TA et al. JAMA Oncol. 2021 Sep 16. doi: 10.1001/jamaoncol.2021.3771.
Key clinical point: In patients with intermediate-/high-risk prostate cancer undergoing radical prostatectomy and lymph node dissection, Gallium 68 prostate-specific membrane antigen (68Ga-PSMA)-11 positron emission tomographic (PET) imaging shows sensitivity and specificity of 0.40 and 0.95, respectively.
Major finding: Compared with histopathology, 68Ga-PSMA-11 PET imaging showed a sensitivity, specificity, positive predictive value, and negative predictive value for pelvic nodal metastases of 0.40, 0.95, 0.75, and 0.81, respectively.
Study details: A single-arm, open-label, phase 3 imaging trial (NCT03368547, NCT02611882, and NCT02919111) of 764 patients with intermediate- to high-risk prostate cancer considered for prostatectomy who underwent 68Ga-PSMA-11 PET scan.
Disclosures: This work is supported by grants from the National Cancer Institute, Prostate Cancer Foundation, Society of Nuclear Medicine and Molecular Imaging, Philippe Foundation Inc, ARC Foundation, German Research Foundation, Doctor Robert Pfleger Foundation, and Wiedenfeld Foundation. The authors received grants, personal fees, cooperation projects, and speaker/advisory/consulting fees; held a patent; and/or reported being founder/shareholder outside this work.
Source: Hope TA et al. JAMA Oncol. 2021 Sep 16. doi: 10.1001/jamaoncol.2021.3771.
Key clinical point: In patients with intermediate-/high-risk prostate cancer undergoing radical prostatectomy and lymph node dissection, Gallium 68 prostate-specific membrane antigen (68Ga-PSMA)-11 positron emission tomographic (PET) imaging shows sensitivity and specificity of 0.40 and 0.95, respectively.
Major finding: Compared with histopathology, 68Ga-PSMA-11 PET imaging showed a sensitivity, specificity, positive predictive value, and negative predictive value for pelvic nodal metastases of 0.40, 0.95, 0.75, and 0.81, respectively.
Study details: A single-arm, open-label, phase 3 imaging trial (NCT03368547, NCT02611882, and NCT02919111) of 764 patients with intermediate- to high-risk prostate cancer considered for prostatectomy who underwent 68Ga-PSMA-11 PET scan.
Disclosures: This work is supported by grants from the National Cancer Institute, Prostate Cancer Foundation, Society of Nuclear Medicine and Molecular Imaging, Philippe Foundation Inc, ARC Foundation, German Research Foundation, Doctor Robert Pfleger Foundation, and Wiedenfeld Foundation. The authors received grants, personal fees, cooperation projects, and speaker/advisory/consulting fees; held a patent; and/or reported being founder/shareholder outside this work.
Source: Hope TA et al. JAMA Oncol. 2021 Sep 16. doi: 10.1001/jamaoncol.2021.3771.